Detalles de la búsqueda
1.
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.
Lung Cancer
; 89(2): 161-6, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26037036
2.
A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin-gemcitabine chemotherapy (GFPC 03-01 Study).
J Thorac Oncol
; 4(3): 364-70, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19155999
Resultados
1 -
2
de 2
1
Próxima >
>>